Topic: triple-negative breast cancer
Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.
Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.
Wall Street analysts pressed Merck for details about whether Keytruda can maintain strong growth as it faces rivals in lung and breast cancer.
Riding high on FDA and EU approvals in triple-negative breast cancer, Roche’s Tecentriq hoped for a win from NICE. The drugmaker didn’t get it.
Merck’s Keytruda may have come up short in metastatic TNBC over the weekend, but in the pre-surgery setting, it posted a first-of its-kind win.